Roche NimbleGen

company

About

Roche NimbleGen provides products and services to the life science research market.

  • 10001 - max

Details

Last Funding Type
Series D
Last Funding Money Raised
$12.50M
Industries
Biotechnology,Genetics,Health Care,Life Science,Market Research
Founded date
Jan 1, 1999
Number Of Employee
10001 - max
Operating Status
Active

Roche NimbleGen provides products and services to the life science research market.


The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents.


The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services.


Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$23M
Roche NimbleGen has raised a total of $23M in funding over 2 rounds. Their latest funding was raised on Apr 17, 2003 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 17, 2003 Series D $12.50M 1 Detail
Oct 17, 2001 Series B $10.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Roche NimbleGen is funded by 1 investors. Tactics II Investments are the most recent investors.
Investor Name Lead Investor Funding Round
Tactics II Investments Series D